title: Effect of Atorvastatin on Expression of Peroxisome Proliferator-activated Receptor Beta/delta in Angiotensin II-induced Hypertrophic Myocardial Cells In Vitro.
abstract: OBJECTIVE
  To explore the effect of atorvastatin on cardiac hypertrophy and to determine the potential mechanism involved.
  
  
  METHODS
  An in vitro cardiomyocyte hypertrophy from neonatal rats was induced with angiotensin II (Ang II) stimulation. Before Ang II stimulation, the cultured rat cardiac myocytes were pretreated with atorvastatin at different concentrations (0.1, 1, and 10 μmol/L). The following parameters were evaluated: the myocyte surface area, 3H-leucine incorporation into myocytes, mRNA expressions of atrial natriuretic peptide, brain natriuretic peptide, matrix metalloproteinase 9, matrix metalloproteinase 2, and interleukin-1β, mRNA and protein expressions of the δ/β peroxisome proliferator-activated receptor (PPAR) subtypes.
  
  
  RESULTS
  It was shown that atorvastatin could ameliorate Ang II-induced neonatal cardiomyocyte hypertrophy in the area of cardiomyocytes, 3H-leucine incorporation, and the expression of atrial natriuretic peptide and brain natriuretic peptide markedly. Meanwhile, atorvastatin also inhibited the augmented mRNA level of several cytokines in hypertrophic myocytes. Furthermore, the down-regulated expression of PPAR- δ/β at both the mRNA and protein levels in hypertrophic myocytes could be significantly reversed by atorvastatin treatment.
  
  
  CONCLUSIONS
  Atorvastatin could improve Ang II-induced cardiac hypertrophy and inhibit the expression of cytokines. Such effect might be partly achieved through activation of the PPAR-δ/β pathway.
authors.affiliation: Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Li
authors.initials: L
authors.lastname: Sheng
authors.affiliation: Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Ye
authors.affiliation: Department of Pharmacology & Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, China.
authors.forename: Yong-xue
authors.initials: YX
authors.lastname: Liu
authors.affiliation: Department of Pharmacology & Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, China.
authors.forename: Chun-guang
authors.initials: CG
authors.lastname: Han
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D000069059:Atorvastatin / Q000494:pharmacology* / Q000627:therapeutic use; D006332:Cardiomegaly / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D002478:Cells, Cultured; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D047494:PPAR delta / Q000235:genetics*; D048068:PPAR-beta / Q000235:genetics*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D047494:PPAR delta; D048068:PPAR-beta; D000804:Angiotensin II; D000069059:Atorvastatin